JPMorgan says Pfizer needs further pipeline progress to change current narrative
After catching up with Pfizer’s Chairman and CEO, CFO, Chief Scientific Officer and Chief Strategy and Innovation Officer at the firm’s healthcare conference, JPMorgan analyst ...
MM&M21h
These CEOs want to market the next Ozempic. Just don’t call it that
The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.
BioSpace22h
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.